The medical community is increasingly viewing systemic inflammation not as a mere symptom, but as a primary driver of chronic disease. BioAge Labs is positioning its experimental pill, BGE-102, at the center of this shift, aiming to mitigate cardiovascular risk by cooling the body’s internal immune response.
In a Phase 1 study involving patients with obesity and elevated inflammation, a 60-milligram dose of BGE-102 reduced high-sensitivity C-reactive protein (hs-CRP)—a standard barometer for systemic inflammation—by 86% over just three weeks. These results closely mirror data from a higher 120-milligram dose, suggesting the drug maintains its potency even at lower concentrations.
Crucially, 87% of participants taking the 60-milligram dose reached hs-CRP levels below 2 milligrams per liter, a clinical threshold associated with a significantly lower risk of heart attacks and strokes. As drugmakers look beyond traditional cholesterol management, the success of oral anti-inflammatories like BGE-102 could redefine preventative care for metabolic and cardiovascular health.
With reporting from STAT News.
Source · STAT News (Biotech)
